Freed AI vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco AI medical scribe delivering SOAP notes within 2 minutes of a visit; no EHR integration needed, making it immediately accessible to solo clinicians and small practices.
About
Freed AI is a San Francisco-based medical technology startup that provides clinicians with an AI-powered medical scribe accessible via mobile app that records patient visit audio, transcribes the conversation, and generates a complete SOAP note formatted for direct paste into any EHR. Freed differentiates from other ambient scribing tools through its simplicity and accessibility — clinicians start and stop recordings with a tap, and notes are delivered within 2 minutes without requiring EHR integrations or complex IT deployment. The product's one-tap workflow and near-immediate turnaround make it accessible to solo practitioners and small clinics that need ambient scribing without enterprise procurement processes. Freed's AI is designed to capture not just what was said but what was clinically significant, filtering conversation content to produce concise, structured notes rather than verbose transcriptions. The company has grown rapidly through physician word-of-mouth and healthcare professional communities, with thousands of clinicians using the product. Founded in 2022, Freed has gained traction as a lightweight, affordable alternative to enterprise ambient scribing platforms.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.